Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche Sees Cancer Combos Start To Deliver

Executive Summary

Roche presented a strong second quarter and was able to highlight a positive debut of Tecentriq, its PD-L1 antagonist, which brought the Swiss group into the lauded programed-death checkpoint inhibitor field.


Related Content

ESMO Preview: Opdivo Under Pressure
Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal
Roche Raises IO Credentials On Tecentriq Lung Cancer Data
Roche's Guide To Success In Oncology
For Roche Immuno-Oncology, It’s Steady As She Goes


Related Companies